Ovid Therapeutics (OVID) EBT Margin Growth (1y) (2022 - 2026)
Powered by 
Analysis
Ovid Therapeutics (OVID) EBT Margin Growth (1y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | -68.00 |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 1,510.00 |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | -3,574.00 |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | -261.00 |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | -2,512.00 |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | -504.00 |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 1,076.00 |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | -101.00 |
| 10 | Ovid Therapeutics | 517.32 Mn | 400.10 Mn | - | -197,293.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -197,293.00 |
| Dec 31, 2025 | 1.35 Mn |
| Sep 30, 2025 | -111,465.00 |
| Jun 30, 2025 | -511,669.00 |
| Mar 31, 2025 | 2,827.00 |
| Dec 31, 2024 | -138,486.00 |
| Sep 30, 2024 | 222,790.00 |
| Jun 30, 2024 | 2.16 Mn |
| Mar 31, 2024 | 1.23 Mn |
| Dec 31, 2023 | 1.41 Mn |
| Sep 30, 2023 | 9.75 Mn |
| Mar 31, 2023 | -1.91 Mn |
| Mar 31, 2022 | -119,571.00 |